Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
WOCKHARDT ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
WOCKHARDT Mar-23 |
ADCOCK INGRAM Jun-14 |
WOCKHARDT/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 316 | 315 | - | |
Low | Rs | 145 | 228 | - | |
Sales per share (Unadj.) | Rs | 184.0 | 93.8 | - | |
Earnings per share (Unadj.) | Rs | -43.1 | -23.6 | - | |
Cash flow per share (Unadj.) | Rs | -25.7 | -19.6 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 231.7 | 73.6 | - | |
Shares outstanding (eoy) | m | 144.09 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.3 | 2.9 | 43.3% | |
Avg P/E ratio | x | -5.3 | -11.5 | 46.6% | |
P/CF ratio (eoy) | x | -9.0 | -13.9 | 64.8% | |
Price / Book Value ratio | x | 1.0 | 3.7 | 27.0% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 33,202 | 45,814 | 72.5% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 6,370 | 2,875 | 221.5% | |
Avg. sales/employee | Rs Th | 0 | 3,688.3 | - | |
Avg. wages/employee | Rs Th | 0 | 669.8 | - | |
Avg. net profit/employee | Rs Th | 0 | -929.4 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 26,510 | 15,834 | 167.4% | |
Other income | Rs m | 1,220 | 111 | 1,100.3% | |
Total revenues | Rs m | 27,730 | 15,945 | 173.9% | |
Gross profit | Rs m | -1,930 | -2,744 | 70.3% | |
Depreciation | Rs m | 2,510 | 683 | 367.3% | |
Interest | Rs m | 3,020 | 429 | 704.1% | |
Profit before tax | Rs m | -6,240 | -3,745 | 166.6% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -30 | 234 | -12.8% | |
Profit after tax | Rs m | -6,210 | -3,990 | 155.6% | |
Gross profit margin | % | -7.3 | -17.3 | 42.0% | |
Effective tax rate | % | 0.5 | -6.2 | -7.7% | |
Net profit margin | % | -23.4 | -25.2 | 93.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 19,140 | 11,597 | 165.0% | |
Current liabilities | Rs m | 34,350 | 6,525 | 526.4% | |
Net working cap to sales | % | -57.4 | 32.0 | -179.1% | |
Current ratio | x | 0.6 | 1.8 | 31.4% | |
Inventory Days | Days | 39 | 111 | 35.5% | |
Debtors Days | Days | 11 | 124 | 8.9% | |
Net fixed assets | Rs m | 48,670 | 6,760 | 720.0% | |
Share capital | Rs m | 720 | 74 | 979.4% | |
Net worth | Rs m | 33,380 | 12,428 | 268.6% | |
Long term debt | Rs m | 2,240 | 4,367 | 51.3% | |
Total assets | Rs m | 70,750 | 23,477 | 301.4% | |
Interest coverage | x | -1.1 | -7.7 | 13.8% | |
Debt to equity ratio | x | 0.1 | 0.4 | 19.1% | |
Sales to assets ratio | x | 0.4 | 0.7 | 55.6% | |
Return on assets | % | -4.5 | -15.2 | 29.7% | |
Return on equity | % | -18.6 | -32.1 | 57.9% | |
Return on capital | % | -9.0 | -19.8 | 45.6% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,530 | 1,352 | 113.2% | |
From Investments | Rs m | -1,250 | -415 | 301.2% | |
From Financial Activity | Rs m | -3,150 | 3,964 | -79.5% | |
Net Cashflow | Rs m | -2,800 | 4,900 | -57.1% |
Compare WOCKHARDT With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare WOCKHARDT With: AJANTA PHARMA SURYA PHARMA PANCHSHEEL ORG VISTA PHARMA BETA DRUGS
Indian share markets continued the momentum as the session progressed and ended the higher.